Kerala Ayurveda Ltd
Incorporated in 1945, Kerala Ayurveda Ltd is engaged In Ayurvedlc services and products[1]
- Market Cap ₹ 292 Cr.
- Current Price ₹ 242
- High / Low ₹ 625 / 220
- Stock P/E
- Book Value ₹ 19.9
- Dividend Yield 0.00 %
- ROCE -10.8 %
- ROE -47.6 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 12.1 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.75% over past five years.
- Promoter holding is low: 33.1%
- Company has a low return on equity of -20.3% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 84.0 to 108 days.
- Promoter holding has decreased over last 3 years: -28.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 28 | 33 | 40 | 44 | 46 | 54 | 43 | 56 | 63 | 73 | 78 | 78 | |
| 23 | 25 | 28 | 35 | 38 | 43 | 51 | 43 | 48 | 58 | 69 | 91 | 99 | |
| Operating Profit | 3 | 3 | 4 | 5 | 6 | 3 | 3 | 0 | 8 | 5 | 4 | -13 | -21 |
| OPM % | 11% | 12% | 12% | 12% | 13% | 6% | 6% | 0% | 14% | 8% | 5% | -16% | -27% |
| 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 3 | 5 | 17 | |
| Interest | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 6 | 6 | 5 | 5 | 4 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 4 |
| Profit before tax | 1 | 2 | 2 | 3 | 3 | 2 | 1 | -7 | 1 | 2 | -0 | -13 | -14 |
| Tax % | 31% | 30% | 31% | 32% | 32% | 31% | 28% | -25% | 28% | -22% | -138% | 2% | |
| 1 | 1 | 2 | 2 | 2 | 1 | 1 | -5 | 1 | 3 | 0 | -14 | -15 | |
| EPS in Rs | 0.98 | 1.05 | 1.64 | 2.08 | 2.18 | 1.14 | 0.83 | -4.69 | 0.84 | 2.74 | 0.04 | -11.45 | -12.69 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 8% |
| 3 Years: | 12% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -679% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 36% |
| 3 Years: | 35% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | -20% |
| 3 Years: | -20% |
| Last Year: | -48% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 12 |
| Reserves | 3 | 3 | 5 | 4 | 7 | 3 | 4 | -1 | 1 | 4 | 21 | 13 | 12 |
| 60 | 64 | 64 | 52 | 70 | 56 | 58 | 66 | 61 | 64 | 64 | 56 | 68 | |
| 5 | 5 | 5 | 9 | 13 | 17 | 21 | 20 | 19 | 21 | 20 | 38 | 38 | |
| Total Liabilities | 79 | 84 | 84 | 76 | 100 | 87 | 94 | 96 | 92 | 99 | 116 | 119 | 130 |
| 18 | 17 | 16 | 16 | 16 | 17 | 17 | 26 | 28 | 30 | 28 | 31 | 32 | |
| CWIP | 0 | 0 | 0 | 6 | 9 | 10 | 12 | 2 | 2 | 0 | 0 | 1 | 1 |
| Investments | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 9 | 9 | 9 |
| 50 | 56 | 57 | 42 | 63 | 49 | 53 | 56 | 50 | 57 | 79 | 77 | 89 | |
| Total Assets | 79 | 84 | 84 | 76 | 100 | 87 | 94 | 96 | 92 | 99 | 116 | 119 | 130 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | 0 | 2 | 2 | -11 | 9 | 5 | -1 | 9 | 9 | -5 | 2 | |
| -2 | -2 | -1 | -2 | -2 | -2 | -4 | -2 | 1 | -5 | -1 | -6 | |
| 1 | 3 | -2 | 1 | 16 | -11 | 0 | 2 | -11 | -2 | 21 | -12 | |
| Net Cash Flow | -1 | 2 | 0 | -0 | 3 | -4 | 1 | -1 | -1 | 2 | 15 | -16 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 56 | 59 | 57 | 60 | 69 | 62 | 83 | 68 | 70 | 74 | 108 |
| Inventory Days | 299 | 283 | 234 | 369 | 380 | 327 | 307 | 238 | 213 | 200 | 183 | 176 |
| Days Payable | 103 | 104 | 58 | 78 | 123 | 115 | 151 | 126 | 122 | 124 | 115 | 90 |
| Cash Conversion Cycle | 257 | 235 | 236 | 348 | 318 | 282 | 218 | 195 | 159 | 146 | 142 | 194 |
| Working Capital Days | -108 | -94 | -69 | -193 | -6 | 54 | 22 | -26 | -157 | -37 | -202 | -53 |
| ROCE % | 3% | 4% | 5% | 6% | 7% | 3% | 4% | -1% | 10% | 6% | 6% | -11% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Preferential Issue
40m - Approved Q3 results; preferential issue converting Rs20.66 crore loan; acquire 26% for Rs99,999,887; EGM Mar 14, 2026
-
Pursuant To Regulation 30 Read With Schedule III Of SEBI (Listing Obligations And Dislcosure Requirements) Regulations, 2015, We Wish To Inform That The Nomination And Remuneration Committee Of The Board Of Kerala Ayurveda Limited Has Approved Grant Of 12,868 Employee Stock Options (Esops) Under Kerala Ayurveda Employee Restricted Stock Unit Plan, 2023 To Eligible Employees Of The Company On February 12, 2026
42m - Board approved Q3 results; preferential issue of 6,30,000 shares converting Rs20.66 crore loan; acquire 26% Ayurvedagram for Rs99,999,887; EGM Mar14,2026.
-
Announcement under Regulation 30 (LODR)-Acquisition
1h - Approved conversion of Rs.20,66,33,700 loan into 6,30,000 shares; acquire 26% for Rs.99,999,887.13; EGM Mar 14, 2026.
- Financial Results For The Quarter Ended 31St December,2025 1h
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th February 2026
1h - Approved Q3 results; preferential conversion of Rs20.66Cr loan into 6.3L shares; acquired 26% Ayurvedagram for Rs99,999,887; EGM Mar14,2026
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2018TranscriptAI SummaryPPT
Business Overview:[1]
Company manufactures Ayurveda products and deals in Ayurveda Research, Academies, Clinics, Hospitals, Ayurvedic Wellness Resorts and Services, cultivation of Ayurveda herbs, and maintaining a herbarium of medicinal plants